Ajovy and Nurtec Comparison

Ajovy®(fremanezumab)	Nurtec®(rimegepant)
Prescription Only Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side...	Prescription Only Nurtec ODT is a medication that can be placed under or onto the tongue to treat migraine symptoms in adults. When taken every other day, it can also be used to prevent episodic...
Administration
Subcutaneous. Learn more.	Oral . Learn more.
Dosing
225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each). Learn more.	Acute treatment of migraine: 75 mg as needed. Preventive treatment of episodic migraine: 75 mg every other day. Maximum daily dose: 75 mg.. Learn more.
Latin Shorthand
225 mg/mo or 675 mg q3mo. Learn more.	Acute treatment of Migraine: 75 mg PRN. Preventive treatment of Episodic Migraine: 75 mg qod.. Learn more.
Out-Of-Pocket Costs With Copay Card
$5. Learn more.	$0. Learn more.
Annual Cap
Patient specific maximum benefit.. Learn more.	Learn more.
Assistance Expiration
12/31/2023. Learn more.	Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.. Learn more.	Acute treatment of migraine: the adverse reaction reported in ≥ 1% of patients treated with NURTEC ODT is nausea. Preventive treatment of episodic migraine: adverse reactions reported in ≥ 2% for rimegepant and ≥ 1% higher than placebo are nausea and abdominal pain/dyspepsia.. Learn more.
Mechanism of Actions (MoA)
CGRP Antagonist. Learn more.	CGRP Antagonist. Learn more.
Special Populations
Is there a pregnancy exposure registry for AJOVY? Yes, there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AJOVY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-927-2605 or visiting www.tevamigrainepregnancyregistry.com. What is the risk associated with the use of AJOVY during pregnancy? There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life, which should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY. However, administration of fremanezumab-vfrm (the active ingredient in AJOVY) to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at doses resulting in plasma levels greater than those expected clinically did not result in adverse effects on development. What is the estimated background risk of major birth defects and miscarriage for the indicated population? The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively, for the U.S. general population. The estimated rate of major birth defects and miscarriage among deliveries to women with migraine are similar to rates reported in women without migraine. Is AJOVY safe to use during lactation? There are no data on the presence of fremanezumab-vfrm (the active ingredient in AJOVY) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AJOVY and any potential adverse effects on the breastfed infant from AJOVY or from the underlying maternal condition. Is AJOVY safe and effective for use in pediatric patients? Safety and effectiveness in pediatric patients have not been established. Is there any information on the use of AJOVY in geriatric patients? Clinical studies of AJOVY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.	Is NURTEC ODT safe to use during pregnancy? There are no adequate data on the developmental risk associated with the use of NURTEC ODT in pregnant women. In animal studies, oral administration of rimegepant during organogenesis resulted in adverse effects on development in rats (decreased fetal body weight and increased incidence of skeletal variations) at exposures greater than those used clinically and which were associated with maternal toxicity. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated rate of major birth defects (2.2 to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Women exposed to NURTEC ODT during pregnancy can participate in a pregnancy exposure registry that monitors pregnancy outcomes. Healthcare providers or patients can contact 1-877-366-0324, email nurtecpregnancyregistry@ppd.com, or visit nurtecpregnancyregistry.com for more information. Can I take NURTEC ODT while breastfeeding? A lactation study conducted on 12 healthy adult lactating women who were between 2 weeks and 6 months postpartum and were administered a single oral dose of rimegepant 75 mg established a relative infant dose of less than 1% of the maternal weight-adjusted dose and a milk-to-plasma ratio of 0.20. These data support that transfer of rimegepant into breastmilk is low. However, there are no data on the effects of rimegepant on a breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NURTEC ODT and any potential adverse effects on the breastfed infant from NURTEC ODT or from the underlying maternal condition. Is NURTEC ODT safe for use in children? Safety and effectiveness in pediatric patients have not been established for NURTEC ODT. Is NURTEC ODT safe for use in elderly patients? In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects. However, clinical studies of NURTEC ODT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Do patients with renal impairment need a dosage adjustment of NURTEC ODT? No, dosage adjustment is not required in patients with mild, moderate, or severe renal impairment. However, NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min). What is the recommended dose of NURTEC ODT for patients with severe renal impairment? The recommended dosage of NURTEC ODT for patients with severe renal impairment (CLcr 15-29 mL/min) is the same as for patients with normal renal function, which is a single dose of 75 mg. However, NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min). Can patients on dialysis use NURTEC ODT? NURTEC ODT has not been studied in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).

Ajovy®(fremanezumab)

Nurtec®(rimegepant)

Prescription Only

Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side...

Prescription Only

Nurtec ODT is a medication that can be placed under or onto the tongue to treat migraine symptoms in adults. When taken every other day, it can also be used to prevent episodic...

Dosage & Administration

Administration

Subcutaneous. Learn more.

Oral . Learn more.

Dosing

225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each). Learn more.

Acute treatment of migraine: 75 mg as needed. Preventive treatment of episodic migraine: 75 mg every other day. Maximum daily dose: 75 mg.. Learn more.

Latin Shorthand

225 mg/mo or 675 mg q3mo. Learn more.

Acute treatment of Migraine: 75 mg PRN. Preventive treatment of Episodic Migraine: 75 mg qod.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$5. Learn more.

$0. Learn more.

Annual Cap

Patient specific maximum benefit.. Learn more.

Learn more.

Assistance Expiration

12/31/2023. Learn more.

Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.. Learn more.

Acute treatment of migraine: the adverse reaction reported in ≥ 1% of patients treated with NURTEC ODT is nausea. Preventive treatment of episodic migraine: adverse reactions reported in ≥ 2% for rimegepant and ≥ 1% higher than placebo are nausea and abdominal pain/dyspepsia.. Learn more.

Mechanism of Actions (MoA)

CGRP Antagonist. Learn more.

Special Populations

Is there a pregnancy exposure registry for AJOVY?

Yes, there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AJOVY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-927-2605 or visiting www.tevamigrainepregnancyregistry.com.

What is the risk associated with the use of AJOVY during pregnancy?

There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life, which should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY. However, administration of fremanezumab-vfrm (the active ingredient in AJOVY) to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at doses resulting in plasma levels greater than those expected clinically did not result in adverse effects on development.

What is the estimated background risk of major birth defects and miscarriage for the indicated population?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively, for the U.S. general population. The estimated rate of major birth defects and miscarriage among deliveries to women with migraine are similar to rates reported in women without migraine.

Is AJOVY safe to use during lactation?

There are no data on the presence of fremanezumab-vfrm (the active ingredient in AJOVY) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AJOVY and any potential adverse effects on the breastfed infant from AJOVY or from the underlying maternal condition.

Is AJOVY safe and effective for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Is there any information on the use of AJOVY in geriatric patients?

Clinical studies of AJOVY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Is NURTEC ODT safe to use during pregnancy?

There are no adequate data on the developmental risk associated with the use of NURTEC ODT in pregnant women. In animal studies, oral administration of rimegepant during organogenesis resulted in adverse effects on development in rats (decreased fetal body weight and increased incidence of skeletal variations) at exposures greater than those used clinically and which were associated with maternal toxicity. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated rate of major birth defects (2.2 to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Women exposed to NURTEC ODT during pregnancy can participate in a pregnancy exposure registry that monitors pregnancy outcomes. Healthcare providers or patients can contact 1-877-366-0324, email nurtecpregnancyregistry@ppd.com, or visit nurtecpregnancyregistry.com for more information.

Can I take NURTEC ODT while breastfeeding?

A lactation study conducted on 12 healthy adult lactating women who were between 2 weeks and 6 months postpartum and were administered a single oral dose of rimegepant 75 mg established a relative infant dose of less than 1% of the maternal weight-adjusted dose and a milk-to-plasma ratio of 0.20. These data support that transfer of rimegepant into breastmilk is low. However, there are no data on the effects of rimegepant on a breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NURTEC ODT and any potential adverse effects on the breastfed infant from NURTEC ODT or from the underlying maternal condition.

Is NURTEC ODT safe for use in children?

Safety and effectiveness in pediatric patients have not been established for NURTEC ODT.

Is NURTEC ODT safe for use in elderly patients?

In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects. However, clinical studies of NURTEC ODT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Do patients with renal impairment need a dosage adjustment of NURTEC ODT?

No, dosage adjustment is not required in patients with mild, moderate, or severe renal impairment. However, NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).

What is the recommended dose of NURTEC ODT for patients with severe renal impairment?

The recommended dosage of NURTEC ODT for patients with severe renal impairment (CLcr 15-29 mL/min) is the same as for patients with normal renal function, which is a single dose of 75 mg. However, NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).

Can patients on dialysis use NURTEC ODT?

NURTEC ODT has not been studied in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).

Ajovy® Alternatives